BTIG Maintains Buy on Globus Medical, Raises Price Target to $78
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Ryan Zimmerman maintains a Buy rating on Globus Medical (NYSE:GMED) and raises the price target from $77 to $78.
October 14, 2024 | 4:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BTIG analyst Ryan Zimmerman has reaffirmed a Buy rating for Globus Medical and increased the price target from $77 to $78, indicating a positive outlook.
The reaffirmation of a Buy rating and a slight increase in the price target by a reputable analyst suggests a positive sentiment towards Globus Medical's stock. This could lead to increased investor confidence and potentially a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100